Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alison Dennis

Latest From Alison Dennis

The Times They Are A-Changin’: Opportunities In Medtech Regulation For The UK After Brexit

The turn of the year is a chance to reflect on times past and the future, to make resolutions and look ahead to changes for the better. With Brexit in mind, this is the time to prophesize on UK medtech’s immediate future.

United Kingdom Market Access

The Times They Are A-Changin’: Opportunities In Medtech Regulation For The UK After Brexit

The end of a calendar year is a chance to reflect on times past and the future, to make resolutions and look ahead to changes for the better. With Brexit in mind, the turn of 2020 is a time to prophesize on UK medtech’s immediate future.

Regulation United Kingdom

Entry into force of UK Bribery Act in sight

Guidance on this important piece of legislation has now been published and the law is set to enter into force in July. Alison Dennis looks at whether the guidance is helpful for medtech companies.

Entry into force of UK Bribery Act in sight

Guidance on this important piece of legislation has now been published and the law is set to enter into force in July. Alison Dennis looks at whether the guidance is helpful for medtech companies.

Entry into force of UK Bribery Act in sight

Guidance on this important piece of legislation has now been published and the law is set to enter into force in July. Alison Dennis looks at whether the guidance is helpful for pharmaceutical companies.

Pharmaceutical Companies: Beware the UK Bribery Act 2010

Alison Dennis urges pharmaceutical companies to review their compliance policies ahead of the Act's entry into force.

See All
UsernamePublicRestriction

Register